CRUK/11/043 (via Uni of Warwick): De-ESCALaTE-HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) vs Standard Chemotherapy early and Late Toxicity Events in Human Papilloma Virus Positive oropharyngeal carcinoma

Medicine & Life Sciences

1. Oropharyngeal Neoplasms 100%
2. Cisplatin 59%
3. Cetuximab 59%
4. Head and Neck Neoplasms 47%
5. Radiotherapy 39%
6. Standard of Care 14%
7. Harm Reduction 12%
8. Therapeutics 8%
9. Survival 8%
10. Clinical Trials 6%
11. Ireland 5%
12. Morbidity 5%
13. Non-Smokers 5%
14. Netherlands 5%